Hong Kong – 17 November 2026 – Jinxin Fertility Group Limited (JXR) disclosed a fresh share repurchase of 2.05 million ordinary shares on 17 November 2026. The on-market transaction was executed within a price range of HK$2.245–2.335 per share, translating into an average cost of approximately HK$2.275 per share and an aggregate cash outlay of HK$4.65 million.
Post-transaction, JXR’s issued share capital (excluding treasury shares) slipped by 0.08 % to 2.62 billion shares, while the company’s treasury share balance climbed to 88.40 million shares from 86.36 million previously. Total outstanding shares, including treasury stock, remained unchanged at 2.71 billion.
Cumulatively, JXR has repurchased 100.94 million shares since receiving its current buyback mandate on 25 June 2026—equivalent to 3.85 % of the shares outstanding on the mandate date. Of these, 92.47 million shares have been bought for cancellation but were still awaiting cancellation as of 17 November 2026. The remaining 8.48 million shares, including the latest batch, are held in treasury.
Under Hong Kong Stock Exchange rules, JXR is subject to a 30-day moratorium—lasting through 17 December 2026—during which it cannot issue new shares or dispose of treasury shares without prior Exchange approval.
Comments